04:38 AM EST, 11/26/2025 (MT Newswires) -- Nyxoah SA ( NYXH ) said Wednesday that the US Centers for Medicare & Medicaid Services has approved a new reimbursement rule, increasing the reimbursement rate applicable to the company's Genio neurostimulation therapy for obstructive sleep apnea.

Effective Jan. 1, 2026, hospital outpatient department reimbursement for the code applicable to Genio will rise 48% to $45,000, while ambulatory surgery centers facility reimbursement will increase 58% to $42,373, the company said.